See more : Nippon Crucible Co., Ltd. (5355.T) Income Statement Analysis – Financial Results
Complete financial analysis of Black Diamond Therapeutics, Inc. (BDTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Diamond Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Strateco Resources Inc. (SRSIF) Income Statement Analysis – Financial Results
- Cerberus Cyber Sentinel Corporation (CISO) Income Statement Analysis – Financial Results
- Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) Income Statement Analysis – Financial Results
- Clarent Corporation (CLRN) Income Statement Analysis – Financial Results
- Shree Pushkar Chemicals & Fertilisers Limited (SHREEPUSHK.NS) Income Statement Analysis – Financial Results
Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| Gross Profit | -437.00K | -3.24M | -2.22M | -600.00K | -47.00K | -44.00K | -24.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 59.35M | 64.44M | 96.83M | 48.21M | 21.75M | 6.95M | 3.45M |
| General & Administrative | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Other Expenses | 0.00 | -354.00K | -2.19M | -1.72M | 6.00K | -16.00K | -6.00K |
| Operating Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Cost & Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Interest Income | 1.92M | 2.03M | 3.46M | 4.04M | 461.00K | 4.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 65.00K |
| Depreciation & Amortization | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| EBITDA | -86.02M | -92.32M | -126.67M | -66.65M | -29.29M | -8.89M | -4.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -86.46M | -92.83M | -126.87M | -69.57M | -8.90M | -8.90M | -4.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.02M | 1.66M | 1.28M | 2.32M | -5.93M | -27.00K | -483.00K |
| Income Before Tax | -82.44M | -88.92M | -125.60M | -67.25M | -35.26M | -8.93M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.40M | -2.39M | -1.78M | 5.89M | -27.00K | 59.00K |
| Net Income | -82.44M | -84.52M | -123.20M | -65.48M | -41.14M | -8.93M | -4.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
| Weighted Avg Shares Out (Dil) | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports